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Research Article
The anti-hypertensive drug prazosin inhibits
glioblastoma growth via the PKCd-dependent
inhibition of the AKT pathway
Suzana Assad Kahn1,2,3,4, Silvia Lima Costa1,2,3,5, Sharareh Gholamin4, Ryan T Nitta4,
Luiz Gustavo Dubois1,2,3,6, Marie Fève7, Maria Zeniou7, Paulo Lucas Cerqueira Coelho1,2,3,5,
Elias El-Habr1,2,3,, Josette Cadusseau8, Pascale Varlet9,10, Siddhartha S Mitra4, Bertrand Devaux1,2,10,11,
Marie-Claude Kilhoffer7, Samuel H Cheshier4, Vivaldo Moura-Neto6, Jacques Haiech7,
Marie-Pierre Junier1,2,3,† & Hervé Chneiweiss1,2,3,*,†
Abstract
A variety of drugs targeting monoamine receptors are routinely
used in human pharmacology. We assessed the effect of these
drugs on the viability of tumor-initiating cells isolated from
patients with glioblastoma. Among the drugs targeting monoamine
receptors, we identified prazosin, an a1- and a2B-adrenergic recep-
tor antagonist, as the most potent inducer of patient-derived
glioblastoma-initiating cell death. Prazosin triggered apoptosis of
glioblastoma-initiating cells and of their differentiated progeny,
inhibited glioblastoma growth in orthotopic xenografts of patient-
derived glioblastoma-initiating cells, and increased survival of
glioblastoma-bearing mice. We found that prazosin acted in
glioblastoma-initiating cells independently from adrenergic recep-
tors. Its off-target activity occurred via a PKCd-dependent inhibi-
tion of the AKT pathway, which resulted in caspase-3 activation.
Blockade of PKCd activation prevented all molecular changes
observed in prazosin-treated glioblastoma-initiating cells, as well
as prazosin-induced apoptosis. Based on these data, we conclude
that prazosin, an FDA-approved drug for the control of hyperten-
sion, inhibits glioblastoma growth through a PKCd-dependent
mechanism. These findings open up promising prospects for the
use of prazosin as an adjuvant therapy for glioblastoma patients.
Keywords glioma; GL261; rottlerin; sh PKCd; dV1.1
Subject Categories Cancer; Neuroscience
DOI 10.15252/emmm.201505421 | Received 7 May 2015 | Revised 17 February
2016 | Accepted 19 February 2016
Introduction
Glioblastoma is the most common and aggressive form of primary
malignant brain tumors. Highly vascularized, infiltrating, and resis-
tant to current therapies, glioblastomas affect patients at different ages
with a median survival shorter than 18 months (Schechter, 1999).
Isolation of tumor cells with stem-like properties from glioblas-
toma has resulted in a novel understanding of tumor behavior.
These glioblastoma-initiating cells (GICs) exhibit long-term self-
renewal and initiate tumors, contributing to the generation of all
subtypes of cells that compose the tumor (Chen et al, 2012b; Cheng
et al, 2013). A growing body of evidence implies GICs as crucial
determinants of tumor behavior, including proliferation, invasion,
and—most importantly—as major culprits of glioblastoma resis-
tance to the standard of care treatments (Bao et al, 2006; Stupp &
Hegi, 2007; Murat et al, 2008; Diehn et al, 2009; Chen et al, 2012a).
Thus, targeting GICs represents one of the main therapeutic chal-
lenges to significantly improve glioblastoma treatments.
Investigation of GIC properties has led to early recognition of
their sensitivity to molecular changes in the micro-environment,
exemplified by the loss of their stem and tumor-initiating properties
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following serum treatment (Singh et al, 2003; Lee et al, 2006;
Gunther et al, 2008; Liu et al, 2009; Silvestre et al, 2011). Within
the brain, tumor cells are exposed to extracellular signals from the
nervous parenchyma. GICs and endothelial cells have been shown
to exert reciprocal control of their properties through release of
extracellular factors (Galan-Moya et al, 2011; Thirant et al, 2012).
Of special interest are molecular signals arising from diffuse neuro-
transmitter systems, which can affect GIC behavior. These
monoaminergic modulator systems control broad central nervous
system functions such as arousal, sleep, food intake, and mood,
which are disrupted in several neuropathological situations.
Although a1-adrenergic receptor (a1-AR) agonists stimulate rodent
neural stem cell (NSC) proliferation and protect them from stress-
induced death (Ohashi et al, 2007; Gupta et al, 2009), their effects
on GICs are unknown.
Many molecules targeting the G protein-coupled receptors
(GPCR) of these monoaminergic systems have been developed and
used safely and effectively for over 40 years in human pharmacol-
ogy. Determining whether GIC properties could be manipulated by
such pharmacological compounds should help proposing adjuvants
to current chemotherapies, or conversely identifying treatments that
may promote tumor progression.
Here, we found that prazosin, a non-selective a1-AR and a selec-
tive a2B-AR antagonist, induced apoptosis in patient-derived GICs
in vitro, and inhibited expansion of tumors initiated by GICs in vivo.
The effect of prazosin occurred via a PKCd-dependent inhibition of
AKT pathway. This effect was independent from adrenergic recep-
tors, revealing a novel off-target activity of prazosin and a novel
therapeutic application for this FDA-approved drug.
Results
Prazosin induces GIC death and inhibits glioblastoma growth
In this study, we used two collections of patient-derived GICs
endowed with stem-like properties isolated in two distinct laborato-
ries (Patru et al, 2010; Silvestre et al, 2011; Fareh et al, 2012;
Thirant et al, 2012). A major feature of these cells is their resistance
to the currently used chemotherapy temozolomide (Patru et al,
2010). The effects of a-AR antagonists on GIC viability were
determined following a 3-day treatment on a patient-derived GIC
culture, TG1 (Patru et al, 2010; Fareh et al, 2012; Thirant et al,
2012). The following antagonists, all known to act as a-AR antago-
nists in the nanomolar range (http://www.bindingdb.org/bind/ByLi
gandName.jsp), were used: prazosin (a1-AR and a2B-AR antagonist),
BMY 7378 (a1D-AR antagonist), terazosin (a2B-AR antagonist), ARC
239 (a2B-AR antagonists), and doxazosin (a1-AR antagonists). Only
prazosin inhibited GIC viability in a robust and concentration-depen-
dent manner (Fig 1A). Prazosin-induced GIC death was also observed
after 24 h of treatment (Fig 1B). Prazosin-induced cell death was
observed in all patient-derived GIC cultures tested (TG1, TG16,
GBM5, and GBM44, Fig 1C). Of note, either GICs bearing the wild-
type (e.g. TG1) or a mutant form of TP53 lacking DNA binding
activity (e.g. TG16) (Silvestre et al, 2011) were sensitive to prazosin
treatment (Fig 1C), indicating that prazosin effect was independent of
the transcription factor P53, a well-known regulator of cell survival.
In addition, we explored whether GICs having escaped a first 72-h
prazosin treatment were responsive to a second prazosin treatment.
The results showed that GICs remained sensitive to 30 lM prazosin
(Fig EV1D). The viability of human fetal brain-derived neural stem
cells/neural progenitor cells (NSC24, NSC25, NSC5031, and
NSC8853), on the other hand, was only marginally decreased at
prazosin concentrations of 10 lM or higher (Fig 1C). Extreme limit-
ing dilution assay (ELDA) was used to further evaluate the targeting
of GICs by prazosin. Frequency of sphere-forming cells, a surrogate
property of GICs (Flavahan et al, 2013), was drastically reduced by
prazosin, dropping from 1/3.88 to 1/248 for TG1 (P = 1.13 1010)
and from 1/6.32 to 1/31 for GBM44 (P = 0.0331) (Figs 1D and EV2).
In addition, we sorted the GIC according to their expression of EGFR,
a marker of malignancy, and of CD133 and CD15, frequently used as
GIC markers (Son et al, 2009). Prazosin also inhibited the survival of
every population subtype, including EGFR+/CD133+/CD15+ cells
(Fig 1E). To further evaluate whether the effectiveness of prazosin is
influenced by the stem and/or differentiated state of the cells, NSCs
and GICs were differentiated along the astroglial, oligodendroglial,
and neuronal lineages (Fig 1F). Prazosin inhibited also the survival of
differentiated glioblastoma cells while minimally affecting differenti-
ated NSCs (Fig 1G).
We then assessed the in vivo effect of prazosin on orthotopic
glioblastoma xenografts from GICs derived from human glioblas-
toma samples (GBM5 and GBM44). EGFR+/CD133+ cells, which
▸Figure 1. Prazosin inhibits GIC survival.A Viability analysis of GICs treated with the a-AR antagonists prazosin, ARC 239, doxazosin, BMY 7378, and terazosin. GICs were treated with the antagonists or
corresponding vehicles for 72 h, and viability was assayed using WST-1. *P < 0.05, n = 4, two-sided Mann–Whitney U-test.
B Quantification of GIC survival using trypan blue exclusion after 24 and 72 h of treatment with prazosin. *P = 0.0286, n = 4, two-sided Mann–Whitney U-test.
C Viability analysis of patient-derived GICs (TG1, TG16, GBM5, GBM44) and NSCs (NSC24, NSC25, NSC5031, NSC8853) treated with prazosin for 72 h. *P = 0.0286, n = 4,
two-sided Mann–Whitney U-test.
D Analysis of the sphere-forming capabilities of GICs using the extreme limiting dilution assay. Cells were seeded in presence of vehicle or 30 µM prazosin (PRZ). Sphere
formation was scored 10 days post-seeding. Frequency of sphere-forming cells: Control = 1/3.88 (lower 8.61, upper 1.95); prazosin 1/248 (lower 1,003, upper 62),
n = 12, P = 1.13 × 1010. Overall test for difference in stem cell number between groups.
E Viability analysis of GICs treated with prazosin after sorting cells according to their expression of EGFR, and the neural stem cell markers CD15 and CD133. Prazosin
inhibits cell viability regardless of CD133 or CD15 expression. *P = 0.0286, n = 4, two-sided Mann–Whitney U-test.
F Immunocytochemical staining of NSCs and GICs cultured in media favoring neuronal (b3-tubulin), astroglial (GFAP), or oligodendroglial (O4) differentiation (Diff
media). b3-tub: b3-tubulin. Scale bar: 20 lm.
G Viability analysis of differentiated NSCs and GICs treated with prazosin for 72 h. Diff: differentiation. *P = 0.0286, n = 4, two-sided Mann–Whitney U-test.
Data information: Results in (A–C, E, G) are presented as mean ± SD in biological quadruplicates from three independent experiments.
EMBO Molecular Medicine ª 2016 The Authors
EMBO Molecular Medicine Prazosin induces glioblastoma apoptosis Suzana Assad Kahn et al
2
B0
50
100
150
V
ia
bi
lit
y 
in
de
x 
(%
 o
f v
eh
ic
le
)
BMY 7378Prazosin TerazosinARC 239 Doxazosin
*
*
*
* * *
*
*
*
0
25
50
75
100
125
Vi
ab
ilit
y 
in
de
x 
 (%
 o
f v
eh
ic
le
)
*
*
*
*
* * *
*
*
*
*
*
*
*
*
*
*
*
*
*
NSC24 NSC25 TG1 TG16 GBM5 GBM44NSC5031 NSC8853
24 hr
72 hr
0 5 10 30
0
25
50
75
100
125
Prazosin (µM)
*
#
*
#
*
#
A
C
D
0 20 40 60 80 100
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
number of cells/well
Vehicle
PRZ 30µM
lo
g 
fra
ct
io
n 
no
n 
re
sp
on
di
ng
E
EGFR+ / CD15high / CD133high
0
10 30 0 10 30
0
50
100
Prazosin (µM)
Vi
ab
ilit
y 
in
de
x 
(%
 o
f v
eh
ic
le
)
*
*
*
*
* * *
*
EGFR+ / CD15low / CD133low
EGFR- / CD15high / CD133high
EGFR- / CD15low / CD133low
F
N
SC
G
IC
ß3-Tub/DAPI GFAP/DAPI O4/DAPI
0 5 10 30
0
50
100
PRZ (µM)
Vi
ab
ilit
y 
in
de
x 
(%
 o
f v
eh
ic
le
)
NSC
GIC
*
#
*
#
0 5 10 30 0 5 10 30
NSC NSC
*
Pro-neuronal Pro-astroglial Pro-oligodendroglial
# #
*
*
*
*
*
*
Diff. media
G
Vi
ab
le
 c
el
l n
um
be
rs
(%
 o
f v
eh
ic
le
)
0 µM 
1 µM 
5 µM 
10 µM 
30 µM 
Prazosin 0 µM 
Prazosin 1 µM 
Prazosin 5 µM 
Prazosin 10 µM 
Prazosin 30 µM 
0 10 30 0 10 30
150
Figure 1.
ª 2016 The Authors EMBO Molecular Medicine
Suzana Assad Kahn et al Prazosin induces glioblastoma apoptosis EMBO Molecular Medicine
3
Vehicle PRZ
0.1
1
10
100
1000
Fo
ld
C
ha
ng
e
in
To
ta
l F
lu
x
*
45 days 
treatment 
Bioluminescent
imaging 
6 weeks 
Selection of 
CD133+/
EGFR+ 
GBM cells 
Transduction 
with GFP-Luc 
construct Injection into  
the striatum 
Detection of tumor 
 by bioluminescent
 imaging   
Randomization 
IP Treatment  
(Control or Prazosin) 
12 weeks 3 weeks Survival andhistological
analysis 
D
G
B
M
44
Ve
hi
cl
e
P
R
Z
G
B
M
5
P
R
Z
Ve
hi
cl
e
B
C
A
G
Vehicle PRZ
0
20
40
60
80
C
D
13
3-
po
si
tiv
e 
tu
m
or
 c
el
ls
(%
 o
f t
ot
al
 G
FP
+ -
ce
lls
)
F
E
i n
Vehicle PRZ
0.01
0.1
1
10
100
Fo
ld
C
ha
ng
e
in
To
ta
l F
lu
x
*
Vehicle PRZ
0.01
0.1
1
10
100
1000
Fo
ld
C
ha
ng
e
in
To
ta
l F
lu
x
*
0 50 100 150
0
50
100
Days
Pe
rc
en
ts
ur
vi
va
l PRZ
P = 0.0084
Tr
ea
tm
en
t
Vehicle
0
0
50
100 200 300
100
Pe
rc
en
ts
ur
vi
va
l
Tr
ea
tm
en
t
Days
PRZ
Vehicle
P = 0.0004
Vehicle
PRZ 
Tumor cells from vehicle-treated mice
Tumor cells from prazosin-treated mice
S
ec
on
da
ry
 g
ra
ft
Ve
hi
cl
e
P
R
Z
P
R
Z 
lo
w
 d
os
e
Vehicle
PRZ
0
100
Pe
rc
en
ts
ur
vi
va
l
0 20 40 60 80 100
50
Days
P = 0.0047
Vehicle PRZ
103
104
105
106
107
To
ta
l f
lu
x 
va
lu
es
*
C
D
13
3-
A
P
C
GFP
Vehicle PRZ
0 50 100 150
0
50
100
Days
Pe
rc
en
ts
ur
vi
va
l
Vehicle
PRZ
P = 0.0031
Tr
ea
tm
en
t
*
Figure 2.
EMBO Molecular Medicine ª 2016 The Authors
EMBO Molecular Medicine Prazosin induces glioblastoma apoptosis Suzana Assad Kahn et al
4
constitute a population of GICs with a high degree of self-renewal
and tumor-initiating ability (Mazzoleni et al, 2010; Emlet et al,
2014), were sorted from primary patient-derived glioblastoma
samples and transduced with a GFP-luciferase construct prior to
injection into mice brains for further bioluminescence imaging.
Forty-five-day-long treatments were initiated once the presence of
tumor masses was confirmed by in vivo bioluminescent imaging
(Fig 2A). Prazosin inhibited glioblastoma growth compared to
control in both xenograft models (Fig 2B–D), and Kaplan–Meier
analysis showed a significant improvement in survival of the
groups treated with prazosin as compared to the control groups
(Fig 2B and C). Histological analysis performed at the end of the
treatment period confirmed that prazosin-treated mice presented
smaller tumors than vehicle-treated mice (Fig 2D). Of note, tumors
from vehicle- and prazosin-treated mice presented similar blood
vessels density, suggesting that prazosin did not affect angiogene-
sis (Fig EV1C). Flow cytometry analysis of GFP-positive tumor
cells showed a significant decrease in human CD133-positive cells
in prazosin-treated mice, suggesting removal of GICs along with
the non-GICs (Fig 2E). To further demonstrate that prazosin
affects GICs, we evaluated its effects on a major property of
cancer stem cells, tumor initiation. GFP-positive tumor cells from
primary tumors were isolated (see Materials and Methods section)
and re-injected into new groups of mice (Fig 2F). All mice that
were grafted with glioblastoma cells isolated from vehicle-treated
mice developed tumors (8/8 cases, Fig 2F). However, only 4/8
mice injected with glioblastoma cells isolated from prazosin-
treated mice developed tumors (Fig 2F). Moreover, mice injected
with glioblastoma cells isolated from prazosin-treated mice
showed a statistically significant survival benefit (P = 0.0047)
(Fig 2F). We also tested lower doses of prazosin (0.15 mg/kg
instead of 1.5 mg/kg) compatible with the human daily regimen
for treatment of hypertension (see Discussion section). The lower
dose of prazosin also induced a significant reduction in tumor
growth and increased survival of glioblastoma-bearing mice
(Fig 2G). To verify whether prazosin effects could also be
observed in an immunocompetent syngeneic mouse model, we
implanted the mouse glioblastoma-like cell line GL261, transduced
with GFP-luciferase, in C57Bl/6 mice brains. Prazosin induced
GL261 cell death in vitro (Fig 3A) and significantly inhibited
tumor growth in vivo (Fig 3B–D), an effect associated with a
survival benefit (Fig 3C). Finally, using this glioblastoma model
coupled with intraperitoneal injections of the green-fluorescent
derivative of prazosin, BODIPY FL prazosin, we observed a
marked accumulation of prazosin in the tumor within 2 h post-
treatment (Fig 3E). Taken altogether, these data show that
prazosin inhibits tumor growth initiated by GICs in vivo and
increases the survival of glioblastoma-bearing mice including at
low doses akin to those used in human treatments.
Prazosin-induced GIC apoptosis is independent from a-AR
We further explored prazosin mechanism of action in GICs. We
first observed that prazosin induced caspase-3 activation in TG1
cells, and this effect was blocked by ZVAD, a caspase inhibitor
(Fig 4A). Interestingly, prazosin did not activate caspase-9,
suggesting that it does not target the intrinsic pathway of apopto-
sis activated by cytotoxic agents such as etoposide (Fig 4B).
Prazosin-induced GIC apoptosis was also observed by FACS analy-
sis of Annexin V and DAPI staining (Fig EV1A). ZVAD prevented
prazosin-induced GIC death, confirming that prazosin triggers GIC
apoptosis (Fig 4C). We further confirmed that prazosin triggers
glioblastoma cells apoptosis in vivo, as glioblastoma cells (GFP-
positive) isolated from prazosin-treated mice presented higher
levels of Annexin V and DAPI staining compared to glioblastoma
cells isolated from vehicle-treated mice (Fig 4D). Of note, prazosin
did not induce apoptosis in non-tumor stromal (GFP-negative)
cells (Fig 4D), further confirming the absence of toxicity of this
drug on normal cells. Using TUNEL staining, we also observed
increased numbers of cells undergoing apoptosis following in vivo
prazosin treatment of mice bearing tumors initiated by GBM44
grafting (Fig EV1B).
◀ Figure 2. Prazosin inhibits glioblastoma growth in vivo.A Schematic representation of prazosin treatment in vivo. EGFR+/CD133+ GICs directly isolated from primary human glioblastoma samples (GBM44 and GBM5) were
transduced with a GFP-luciferase construct and orthotopically implanted into the striatum of NSG mice. Treatment was initiated once the tumors were detected
and bioluminescent analyses of tumor growth were performed after 45 days of treatment.
B, C In vivo effect of prazosin treatment (1.5 mg/kg) on glioblastoma growth. Tumors were initiated with GBM44 GICs (B) or GMB5 GICs (C). Left panels: Bioluminescent
in vivo images of tumors in mice treated with prazosin (PRZ) or vehicle for 45 days. Middle panels: Quantification of the bioluminescent signals. Fold change in
total flux represents the ratio: total flux after treatment/total flux before treatment. *P = 0.0002 and *P = 0.003 for GBM44 and GBM5, respectively, n = 8,
two-sided Mann–Whitney U-test. Right panels: Kaplan–Meyer survival curves of mice treated with prazosin (PRZ) or vehicle demonstrating a significant survival
benefit of prazosin as compared to vehicle, log-rank Mantel–Cox test. The treatment period is shaded in gray.
D Example of hematoxylin/eosin staining of brain coronal sections from mice sacrificed after 45 days of treatment with prazosin (PRZ) or vehicle. i: tumor infiltration.
n: tumor necrosis. Scale bar: 2 mm. GBM44 GICs.
E Left panel: Representative flow cytometry plots depicting the percentage of CD133+ glioblastoma cells (GFP+) isolated from mice treated with prazosin (PRZ) or
vehicle. Tumors were initiated with GBM44 GICs. Right panel: Quantification of flow cytometry analyses of CD133 expression by GFP+-tumor cells isolated from
xenografts of three prazosin-treated (PRZ) mice and three vehicle-treated mice. *P = 0.0003, n = 6, two-sided Mann–Whitney U-test. Results are presented as
mean  SD in biological quadruplicates from six independent experiments.
F Secondary grafting of tumor cells (GBM44-GFP+) isolated from vehicle- or prazosin-treated mice bearing primary tumors. Mice injected with glioblastoma cells
isolated from prazosin-treated mice developed tumors at a lower frequency (50% versus 100%). Moreover, mice injected with glioblastoma cells isolated from
prazosin-treated mice presented a statistically significant survival benefit. Left panel: Bioluminescent in vivo images of secondary grafts. Middle panel:
Quantification of the bioluminescent signals. *P = 0.0004, n = 8, two-sided Mann–Whitney U-test. Right panel: Kaplan–Meyer survival curves of mice bearing
secondary graft from glioblastoma cells isolated from vehicle- and prazosin-treated mice.
G Inhibitory effect of low doses of prazosin (0.15 mg/kg) on glioblastoma growth in vivo. Left panel: Bioluminescent in vivo images of tumors in mice treated with
vehicle or prazosin (PRZ) for 45 days. Tumors were initiated with GBM44 GICs (compare with panel B). Middle panel: Quantification of the bioluminescent signals.
*P = 0.0007, n = 8, two-sided Mann–Whitney U-test. Right panel: Kaplan–Meyer survival curves of mice demonstrating a significant survival benefit of a treatment
with low doses of prazosin, log-rank Mantel–Cox test. The treatment period is shaded in gray.
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Cell cycle was mostly not affected by prazosin. Although we
observed a dose-dependent reduction in BrdU incorporation in vitro
in GICs that had survived a 24-h prazosin exposure, and a decrease in
Ki67 staining in tumor grafts of prazosin-treated mice (Fig EV3A and
B), no change was observed in cyclin D1, cyclin D3, and CDK2 levels,
which are required for G1/S transition (Fig EV3C).
Prazosin is known as a non-selective antagonist of a1-AR and as
a selective antagonist of a2B-AR (Bylund et al, 1994). Prazosin
inhibited GIC survival in a concentration-dependent manner, with
an EC50 value of 7.88 lM (6.70–9.28) (Fig 4E), several orders of
magnitude above the nanomolar concentrations at which prazosin
acts on a-ARs (http://www.bindingdb.org/bind/ByLigandName.
jsp). Having observed that the a2B-AR antagonists terazosin and
ARC 239 did not mimic prazosin effect on GIC viability (Fig 1A), we
sought to test whether cirazoline, a non-selective subtype agonist of
a1-AR, would reverse prazosin-induced GIC death. Cirazoline did
not affect GIC viability, and only partially rescued prazosin-induced
cell death (Fig 4F). Accordingly, radio ligand assays showed that
prazosin binding sites were not detected in GIC membrane prepara-
tions (Fig 4G). Considering the reported stimulation of the ERK/
MAPK pathway by a-AR ligands (Benoit et al, 2004; Liou et al,
2009), and the reported participation of this signaling pathway in
the promotion of GIC survival (Sunayama et al, 2010), we analyzed
the effect of prazosin on ERK/MAPK pathway in GICs. In contrast to
the expected effect for an a-AR antagonist, prazosin induced ERK
phosphorylation in these cells (Fig 4H). ERK/MAPK pathway activa-
tion in GICs was confirmed by SRE-luciferase reporter assay, which
is a measure of luciferase reporter expression driven by the serum
response element downstream of the ERK/MAPK pathway (Fig 4I).
Finally, the ERK/MAPK pathway inhibitor U0126 did not protect the
GICs from prazosin (Fig 4J), confirming that prazosin-induced GIC
death was independent of ERK/MAPK pathway activity. Altogether,
these results indicate that prazosin’s effect on GICs is independent
of AR- and ERK-/MAPK-signal transduction pathway.
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Figure 3. Prazosin inhibits glioblastoma growth in immunocompetent mice.
A Viability analysis of GL261 treated with prazosin in vitro. *P = 0.0286, n = 4, two-sided Mann–Whitney U-test. Results are presented as mean  SD in biological
quadruplicates from six independent experiments.
B Schematic representation of prazosin treatment in vivo of glioblastoma-bearing immunocompetent mice.
C Prazosin inhibits in vivo tumor growth in an immunocompetent model of glioblastoma. Left panel: Bioluminescent in vivo images of tumors in C57Bl/6 mice treated
with vehicle or prazosin (PRZ) for 14 days. Middle panel: Quantification of the bioluminescent signals. *P = 0.0002, n = 8, two-sided Mann–Whitney U-test. Right
panel: Kaplan–Meyer survival curves of mice treated with prazosin (PRZ) or vehicle. Log-rank Mantel–Cox test. The treatment period is shaded in gray.
D Hematoxylin/eosin staining of C57Bl/6 mice brain coronal sections sacrificed after 14 days of treatment with prazosin. Scale bar: 2 mm.
E Fluorescence imaging of GL261 intra-striatal grafts at 1 and 2 h after an intraperitoneal injection of BODIPY FL prazosin, the green-fluorescent derivative of prazosin.
Scale bar: 2 mm.
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PKCd is involved in prazosin-induced GIC apoptosis
PKCd is a member of the family of novel protein kinase C (nPKC)
isoforms, which has been shown to promote apoptosis by acting
both upstream and downstream of caspase-3 (Basu et al, 2001;
Lu et al, 2007). Immunoblotting showed that GICs expressed higher
levels of PKCd compared to NSCs (Fig 5A). Of note, GICs and
glioblastoma cells that differentiated along the astroglial, oligoden-
droglial, and neuronal lineages expressed similar levels of PKCd
(Fig EV4A). Immunocytochemical detection of PKCd in TG1 cells
revealed enhanced punctate nuclear staining in prazosin-treated
GICs, as compared to vehicle-treated GICs (Fig 5B). As caspase-3
activation is known to induce PKCd cleavage into a 41 kDa catalytic
fragment (Basu et al, 2001; Lu et al, 2007), we investigated the
presence of PKCd catalytic fragment in prazosin-treated GICs.
Immunoblotting analysis revealed that prazosin induced the cleav-
age of PKCd into its 41 kDa catalytic fragment (Fig 5C). Rottlerin, a
selective PKCd inhibitor (Gschwendt et al, 1994), prevented
prazosin-induced PKCd cleavage in GICs (Fig 5C). Moreover,
prazosin-induced caspase-3 activation in GICs was also prevented
by rottlerin (Fig 5D) suggesting that PKCd activation is necessary
for the processing of caspase-3 in GICs. We then investigated
whether the inhibition of PKCd could rescue GICs from prazosin-
induced cell death. In addition to rottlerin, we used the peptide
dV1.1 that specifically opposes PKCd mobilization (Chen et al,
2001) and silenced the expression of PKCd using shRNA (Fig EV4B).
Rottlerin (Fig 5E), dV1.1 (Fig 5F), and PKCd shRNA (Fig 5G) signifi-
cantly rescued GICs from prazosin-induced glioblastoma cell death.
Figure 4. Prazosin induces GIC apoptosis independently from a-AR.
A Immunoblotting for pro-caspase-3 (pro-CASP3) and active caspase-3 (CASP3) in GICs treated with prazosin (PRZ) or vehicle (V) demonstrating that prazosin activates
caspase-3. ZVAD, a caspase inhibitor, prevents prazosin-induced caspase-3 activation. kDa: kilodaltons.
B Immunoblotting for pro-caspase-9 (pro-CASP9) and active caspase-9 (CASP9) in GICs treated with prazosin (PRZ) or vehicle (V) demonstrating that prazosin does not
activate caspase-9.
C Viability analysis of GICs treated with prazosin for 24 h in the presence or absence of ZVAD, a caspase inhibitor. ZVAD counteracts prazosin-induced GIC death.
*P = 0.0286, n = 4, two-sided Mann–Whitney U-test. Results are mean  SD in biological quadruplicates from three independent experiments.
D Prazosin induces glioblastoma cell apoptosis in vivo. GFP+ and GFP cells were analyzed from tumors in vehicle (upper panel) or prazosin-treated (lower panel) mice.
Annexin V/DAPI staining was used to identify apoptotic cells by FACS. Tumors were initiated by GBM44 GICs implantation.
E Dose–response curve of prazosin on GIC survival (24 h treatment). EC50 was determined with curve fit using nonlinear regression. Results are mean  SD in
biological triplicates from one experiment out of three independent experiments giving similar results.
F Viability analysis of GICs treated with prazosin for 24 h in the presence or absence of cirazoline, a subtype agonist of the a-ARs. Cirazoline did not alter GIC survival
and counteracted only poorly prazosin-induced GIC death. *P < 0.05, n = 4, two-sided Mann–Whitney U-test. Results are mean  SD in biological quadruplicates
from three independent experiments.
G Membrane binding assays demonstrating the absence of prazosin binding sites in GIC membrane preparations. Positive control shows that prazosin binds to
membrane preparations of yeast expressing a1-AR. PRZ: prazosin. CRZ: cirazoline.
H Immunoblotting for phosphorylated ERK1/2 (P-ERK1/2) and total ERK1/2 following prazosin treatment for 30 min. Prazosin induces ERK1/2 phosphorylation in GICs.
I SRE-luciferase reporter activity analysis of GICs treated with prazosin in absence or presence of U0126 (10 lM), an inhibitor of the ERK-activating kinase MEK. U0126
prevented prazosin-induced SRE-luciferase activation in GICs. Results are from three independent experiments.
J Viability analysis of GICs treated with prazosin for 24 h in the presence or absence of U0126 (10 lM), an inhibitor of the ERK-activating kinase MEK. U0126 did not
counteract prazosin-induced GIC death. Blockade of prazosin-induced ERK1/2 phosphorylation by U0126 was confirmed by immunoblotting (insert). PRZ: prazosin.
Results are presented as mean  SD in biological quadruplicates from three independent experiments.
Source data are available online for this figure.
▸Figure 5. Prazosin induces GIC apoptosis in a PKCd-dependent manner.A PKCd expression analysis in two patient-derived GICs and NSCs by immunoblotting. GICs express higher levels of PKCd than NSCs. kDa: kilodaltons.
B PKCd detection by immunostaining (green). Nuclei were stained with DAPI (blue). Enhanced PKCd punctate nuclear expression in prazosin-treated (PRZ, 5 lM) GICs,
as compared to vehicle-treated GICs. PRZ: prazosin. Scale bar: 10 lm.
C Total PKCd (PKCd 78 kDa) and cleaved PKCd (PKCd 41 kDa) expression analysis in GICs by immunoblotting. Prazosin (PRZ) induces PKCd cleavage into a 41 kDa
active fragment. 2 lM rottlerin (Rott), a PKCd inhibitor, inhibits prazosin-induced PKCd cleavage. V: vehicle. kDa: kilodaltons.
D Pro-caspase-3 (Pro-CASP3) and activated caspase-3 (CASP3) expression analysis in GICs by immunoblotting. 2 lM rottlerin (Rott) inhibits prazosin (PRZ)-induced
caspase-3 activation. V: vehicle. kDa: kilodaltons.
E Inhibition of PKCd by rottlerin prevents, in a concentration-dependent manner, prazosin-induced GIC death. Viability analysis of GICs treated with prazosin for 72 h
in the presence or absence of rottlerin. *P = 0.0286, n = 4, two-sided Mann–Whitney U-test. Error bars mean  SD.
F Inhibition of PKCd by the specific anti-PKCd RACK peptide dV1.1 (10 lM) counteracts prazosin-induced GIC death. Viability analysis of GICs treated with prazosin
for 72 h in the presence or absence of dV1.1. *P < 0.005 for prazosin 1 and 5 µM and P < 0.001 for Prazosin 10 µM by two-tailed unpaired Student’s t-test, n = 4.
Error bars mean  SD.
G Decreased PKCd expression using shRNA counteracts prazosin-induced GIC death. Viability analysis of GICs transduced with scrambled or PKCd shRNA and treated
with prazosin for 72 h. *P < 0.005 by two-tailed unpaired Student’s t-test, n = 4. Error bars mean  SD.
H Prazosin inhibits AKT phosphorylation in GICs. LY294002 (LY, 30 lM), an inhibitor of the PI3K/AKT pathway, was used as a positive control. Terazosin, which does
not affect GIC viability, does not alter AKT phosphorylation (see the corresponding cell viability counting in Fig EV4C). Phosphorylated AKT (P-AKT) and total AKT
(AKT) expression analysis in GICs by immunoblotting. V: vehicle. kDa: kilodaltons.
I Prazosin (10 lM) does not inhibit AKT phosphorylation in NSCs. Analysis by immunoblotting. V: vehicle. kDa: kilodaltons.
J b-catenin expression, a downstream target of AKT, is decreased in prazosin-treated GICs, as opposed to NSCs. Analysis by immunoblotting. V: vehicle. kDa:
kilodaltons.
K, L Inhibition of PKCd using rottlerin (Rott, 2 lM) or dV1.1 (10 lM) counteracts prazosin inhibition of AKT phosphorylation. Analysis by immunoblotting. V: vehicle. kDa:
kilodaltons.
Source data are available online for this figure.
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As novel PKC isoforms have been shown to curtail AKT activation
(Li et al, 2006), a signaling pathway reported to be crucial to GIC
survival (Eyler et al, 2008; Bleau et al, 2009), we examined the
effect of prazosin on PI3K/AKT pathway in GICs. Prazosin inhibited
AKT phosphorylation in GICs as efficiently as LY294002, a specific
PI3K inhibitor (Fig 5H, left panel). Terazosin, used as a control
since it does not affect GICs survival (Fig EV4C), did not modify
AKT phosphorylation (Fig 5H, right panel). In addition, prazosin
did not alter the levels of phosphorylated AKT (P-AKT) in NSCs
(Fig 5I). To further investigate prazosin effects on AKT activity, we
analyzed the levels of b-catenin expression, one of AKT downstream
targets. Activated AKT is known to phosphorylate and thereby
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inactivate GSK-3b, leading to stabilization of the transcription factor
b-catenin (Yost et al, 1996; Pap & Cooper, 1998). As expected,
prazosin-treated GICs showed reduced b-catenin levels as compared
to vehicle-treated GICs (Fig 5J). Conversely, prazosin did not affect
b-catenin levels in NSCs (Fig 5J). We then exposed GICs to prazosin
in the presence or absence of rottlerin (Fig 5K) or dV1.1 (Fig 5L)
and assessed the levels of P-AKT. Rottlerin as well as dV1.1
counteracted prazosin-induced inhibition of AKT phosphorylation
(Fig 5K and L). The role of PKCd was further investigated in vivo.
Silencing the expression of PKCd with shRNA (Fig EV4B) slowed
the growth of the tumors (Fig 6B, Prior-PRZ images). Interestingly,
analysis of mRNA profiles of adult glioblastoma available in the
TCGA dataset showed that high expression of PKCd is associated
with a poorer prognosis for patients. High PKCd (PRKCD) mRNA
levels were inversely correlated with overall survival as well as
progression-free survival (Fig EV5). This result suggests that PKCd
expression is necessary for GIC tumor growth in vivo, and is consis-
tent with the reported inhibitory effects of PKCd shRNA on the
growth of xenografts of prostate, pancreas, and breast cancer stem
cells (Chen et al, 2014). We then analyzed whether prazosin could
still inhibit the growth of PKCd-silenced tumors in vivo. As expected,
prazosin inhibited the growth of control (shScramble) tumors
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Figure 6. Prazosin inhibits glioblastoma growth in vivo in a PKCd-dependent manner.
A Schematic representation of the experimental design.
B Bioluminescent in vivo images of tumors in mice grafted with GICs expressing either scrambled (upper panel) or PKCd (lower panel) shRNA. All mice were treated
with prazosin (PRZ) for 45 days.
C Quantification of the bioluminescent signals showing that decreased expression of PKC counteracts prazosin inhibition of tumor growth. Fold change in total flux
represents the ratio: total flux after treatment/total flux prior treatment. *P = 0.0007, n = 8, two-sided Mann–Whitney U-test.
D Schematic representation of the molecular mechanisms underlying prazosin-induced GIC apoptosis. See text for details.
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(Fig 6B, upper panel). On the other hand, PKCd-silenced tumors
were no longer responsive to prazosin treatment (Fig 6B, lower
panel and Fig 6C), further confirming the involvement of PKCd in
prazosin-induced glioblastoma cell death.
Taken together, these results show that prazosin-induced PKCd
activation leads to AKT pathway inhibition. PKCd-dependent AKT
inhibition is accompanied by caspase-3 activation, generating a
PKCd catalytic fragment, ultimately leading to GIC apoptosis
(Fig 6D).
Discussion
Comparative analysis of a-AR antagonists on cell survival using
patient-derived GICs showed that only prazosin inhibited GIC viabil-
ity in a robust and concentration-dependent manner. Moreover,
prazosin inhibited the growth of glioblastoma in orthotopic xeno-
graft mouse models and increased mice survival, with no toxicity.
We demonstrate that prazosin-induced GIC apoptosis involves a
PKCd-dependent inhibition of AKT pathway.
The a-AR family includes three a1 and three a2 subtypes.
Prazosin has been extensively characterized as a non-selective
subtype antagonist of a1-AR and a selective subtype antagonist of
a2B-AR (Bylund et al, 1994). We found that prazosin acted on GICs
independently from ARs. Membrane preparations of GICs did not
show prazosin binding sites. Cirazoline, a non-selective subtype
agonist of a-AR did not alter GIC survival, and mildly counteracted
prazosin-induced GIC death. In addition, prazosin activated the
MAPK/ERK signaling pathway in GICs, an observation that
contrasts with the expected inhibitory effect of a-AR blockage on
this signaling pathway (Benoit et al, 2004; Liou et al, 2009). Alto-
gether, these data demonstrate an off-target mechanism of action for
prazosin on GICs.
Caspase-3 activation in GICs exposed to prazosin, and prevention
of prazosin-induced GIC death by ZVAD, an inhibitor of caspase
activation, revealed that the type of death induced by prazosin in
GIC is apoptosis. Other quinazoline-related compounds such as
doxazosin and terazosin, shown here to only marginally affect GICs,
have been reported to exert pro-apoptotic effects on prostate cancer
cells independently from ARs, through the activation of TGFb
signaling pathway (Desiniotis & Kyprianou, 2011). A pro-apoptotic
action of prazosin has been reported in the K562 erythroleukemia
cell line, where prazosin has been shown to enter the cells and bind
intracellular proteins (Fuchs et al, 2011). The reason why prazosin
is the most effective of the quinazolines on GICs remains to be
determined. Interestingly, a preferential prazosin toxicity, among
other quinazoline-based alpha-adrenoreceptor antagonists, has been
reported on prostate cancer cells, 10 lM prazosin being in this case
more effective than 100 lM doxazosin in inducing DNA damage
(Lin et al, 2007).
We describe here a novel mechanism where prazosin-induced
GIC apoptosis includes a mechanism dependent on PKCd activation,
a critical pro-apoptotic signal in various cell types (Leverrier et al,
2002; Brodie & Blumberg, 2003; Reyland, 2007; Larroque-Cardoso
et al, 2013). Whether prazosin binds directly to PKCd remains to be
determined. PKCd is known to promote apoptosis through its consti-
tutively activated form, the 41 kDa PKCd catalytic fragment. Genera-
tion of the PKCd catalytic fragment depends on caspase-3 activation.
Caspases are the main effectors of apoptosis and are activated in
response to apoptotic stimuli by limited proteolytic cleavage, an
event prevented by AKT activation (Salvesen & Riedl, 2008). AKT is
a serine–threonine kinase that regulates cell survival in various
types of cells (Parcellier et al, 2008), including GICs (Eyler et al,
2008; Bleau et al, 2009). Our results show that the effect of prazosin
on GICs depends on the inhibition of the AKT signaling pathway,
which may occur in response to PKCd activation (Fig 5). PKCd-
dependent AKT inhibition is accompanied by the activation of
caspase-3, a downstream target of AKT. Blockade of PKCd
prevented prazosin-induced caspase-3 activation, suggesting that
PKCd activation is required for the processing of caspase-3. More-
over, prazosin-induced GIC apoptosis is mostly dependent on PKCd
activation, resulting in AKT signaling pathway inhibition. Alto-
gether, our results demonstrate PKCd as a novel protagonist in GIC
apoptosis. In addition, these data may improve the prospects for
targeting other cancer cells known to exhibit altered PKCd signaling
(Bosco et al, 2011).
Prazosin effects were observed not only in vitro, but also in vivo,
using orthotropic implants of patient-derived GICs. The importance
of targeting GICs stems from repeated descriptions of the increased
tumor-seeding potential of these cells and their resistance to a vari-
ety of chemotherapy and radiation treatments, as compared to the
other tumor cell populations (Eyler & Rich, 2008; Zhu et al, 2014).
Failure of current therapies to eradicate the disease is likely caused
by the replenishment of the tumor by GICs spared by the treatment
(Chen et al, 2012a). Development of effective treatments targeting
GICs requires not only understanding the molecular mechanism of
action of the novel compound but also determining the drug’s safety
in patients. Our data demonstrate that prazosin is highly active on
GICs and their differentiated progeny, both in vitro and in vivo,
whereas it marginally affects the survival of NSCs, or NSCs differen-
tiated along either of the three neural lineages. Although the signal-
ing pathways sustaining maintenance of NSCs and GICs differ in
several ways, they both require a proper functioning of the PI3K/
AKT pathway for their survival (Groszer et al, 2006; Yan et al,
2013). Accordingly, no change in AKT phosphorylation was
observed in NSCs following prazosin treatment. This result, associ-
ated with the paucity of PKCd levels in NSCs as compared to GICs,
suggests that a preliminary activation of PKCd is mandatory for
prazosin to exert its pro-apoptotic action. The possibility that addi-
tional molecular mechanisms are involved in prazosin-induced cell
death cannot be excluded but remains to be elucidated. An effect of
prazosin on adult human neural cells cannot be excluded since we
used human NSCs of embryonic origin, although no deleterious
effect of prazosin was observed (see Figs 2D, 3D, and 4D) or has
been reported so far in mouse brain following administration of
doses akin to the ones we used.
Prazosin is a clinically approved drug and has been adopted for
more than 40 years in clinical practice to treat hypertension (Cavero
& Roach, 1980). Its use has been extended to treat benign prostatic
hyperplasia, congestive heart failure, pheochromocytoma, sleep
problems associated with post-traumatic stress disorder, and
Raynaud’s disease (http://www.ncbi.nlm.nih.gov/pubmedhealth/
?term=prazosin). The inhibition of glioblastoma growth in vivo and
extended survival of glioblastoma-bearing mice in the presence of
prazosin support the use of prazosin as an adjuvant treatment for
glioblastoma patients.
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The current use of prazosin hydrochloride in humans as an oral
prescription for hypertension is, according to the FDA recommenda-
tion, a total daily dose of 20 mg that may be further increased up
to 40 mg given in divided doses. Bioavailability studies have
demonstrated peak levels of approximately 65% of the drug in solu-
tion (http://www.fda.gov/Safety/MedWatch/SafetyInformation/
Safety-RelatedDrugLabelingChanges/ucm155128.htm). The daily
dosage already approved is therefore likely to result in a bioavail-
ability of prazosin in the 5–10 lM range, shown here to effectively
induce GIC apoptosis in vitro. Such a potential use as adjuvant ther-
apy in humans is further supported by our observations that low
doses of prazosin (0.15 mg/kg should be extrapolated to 9 mg for
an adult of 60 kg) also significantly inhibited tumor growth in vivo.
Prazosin-induced patient-derived GIC apoptosis and inhibition of
glioblastoma growth in vivo through a PKCd-dependent mechanism
of action, associated with the well-established and documented use
of this drug in clinical settings, opens a promising possibility for its
use in glioblastoma treatment.
Materials and Methods
Cell culture
Patient-derived GICs (TG1, TG16, GBM5, GBM44) were isolated
from glioblastoma neurosurgical resections, and their stem-like
properties (i.e., clonogenicity, self-renewal, expression of neural
stem cell markers) and tumor-initiating properties were previously
characterized (Patru et al, 2010; Galan-Moya et al, 2011; Silvestre
et al, 2011; Fareh et al, 2012; Emlet et al, 2014). All cell cultures
were authenticated by STR profiling, and absence of mycoplasma
was controlled. Sequencing RT–PCR products of TP53 and PTEN
transcripts showed the wild-type forms of both genes in TG1 GICs
and mutant forms in TG16 GICs (Silvestre et al, 2011). Neural stem
cells/neural progenitor cells (NSC24, NSC25, NSC5031, NSC8853)
were derived from electively terminated human fetal brains, and
characterized as previously described (Thirant et al, 2011). NSCs
expressed the neural stem cell markers Sox2, Bmi1, and Nestin
(Thirant et al, 2011). GICs and NSCs were cultured as floating cellu-
lar spheres as previously described (Patru et al, 2010; Thirant et al,
2011; Feve et al, 2014).
Chemicals and antibodies
ARC 239 dihydrochloride (selective a2B-AR antagonist), BMY 7378
dihydrochloride (high-affinity a1D-AR antagonist), doxazosin mesy-
late (selective a1-AR antagonist), prazosin hydrochloride (non-
selective a1 and selective subtype a2B-AR antagonist), terazosin
hydrochloride (selective a1-AR and a2B-AR antagonist), and cirazo-
line (selective a1-AR agonist) were purchased from Tocris Cookson
Inc. U0126 (MEK inhibitor), LY294002 (PI3K inhibitor), and ZVAD
(caspase inhibitor) were purchased from Calbiochem. Rottlerin
(PKCd inhibitor) was from Sigma (Lyon, France). Delta V1.1 was
kindly provided from Daria Mochly group (Chen et al, 2001).
BODIPY FL Prazosin was from Thermo Scientific. The antagonists
and the inhibitors were dissolved in dimethyl sulfoxide (DMSO,
Sigma) or water, according to the manufacturer’s instructions. Cells
were treated with a single dose of antagonists, inhibitors, or the
corresponding volume of vehicle. Inhibitors were added 30 min
before the addition of prazosin.
Primary antibodies against the following proteins were used:
PKCd (Santa Cruz Biotechnologies), phospho-p42/p44 ERK (Cell
Signaling), p42/p44 ERK, b-tubulin (Millipore), phospho-AKT, AKT,
cleaved caspase-3, caspase-3, cyclin D1, cyclin D3, CDK2 (Cell
Signaling), b-catenin (BD Biosciences), a-actin (Chemicon
International), CD133/1-APC, CD133/2-APC (Miltenyi Biotech),
GFAP (Synaptic Systems), O4 (R&D), Ki67 (Thermo Scientific), and
EGFR-Alexa 488 (Biolegend). The secondary antibodies were Alexa
488-conjugated goat anti-rabbit (Life Technologies), anti-mouse IgG,
and anti-rabbit IgG (both from GE Healthcare). See Appendix Table
S1 for references and dilutions.
Cell viability and proliferation assays
Cells were plated in 96-well plates at 2 × 104 cells/well and
treated with the appropriate compounds at 37°C, 5% CO2. Cell
viability was assessed using reduction in WST-1 (4-[3-(4-iodo-
phenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate,
Roche, France) to water-soluble formazan. At the end of the incu-
bation period, 10% (v/v) WST-1 was added to the culture media,
and the cells were further cultured for 3 h. The absorbance was
measured at 430 nm in a microplate reader (Expert Plus V1.4
ASYS). Cell viability was also verified with cell counting following
addition of trypan blue (Sigma) at a final concentration of 0.1%
(v/v), and routine examination of the cells under phase contrast
microscopy. Cell proliferation was assessed using the Cell Prolifer-
ation ELISA (Roche), which allows immunochemiluminescent
detection of BrdU incorporation into newly synthesized DNA of
replicating cells, following the manufacturer’s instructions. Light
emission was measured using a luminometer (EnVision Multilabel
Reader 2104 PerkinElmer). Data were normalized relative to the
vehicle-treated controls.
Limiting dilution assays
Cells were plated in 96-well plates at 1, 5, 10, 20, 50, and 100 cells/
well/100 ll as previously described (Patru et al, 2010). The percent-
age of wells with neurospheres was determined after 10 and
21 days. Analysis was performed with software available at http://
bioinf.wehi.edu.au/software/elda/ (Hu & Smyth, 2009).
Membrane binding assays
Cellular spheres were dissociated in phosphate-buffered saline
(PBS) and subjected to two rounds of resuspension in 10 ml of cold
PBS followed by centrifugation at 210 g at 4°C. Cells were then
resuspended in 10 ml of lysis buffer composed of 10 mM HEPES,
2 mM EGTA at pH 7.4, in the presence of 1× protease inhibitor cock-
tail (Roche). After centrifugation at 210 g, the pellet was resus-
pended in 1 ml of lysis buffer and incubated for 20 min on ice. The
solution was then homogenized and passed 25 times through a 18G
needle. After centrifugation at 3,000 g for 10 min, the supernatant
was collected and centrifuged at 21,000 g for 2 h. The pellet was
resuspended in lysis buffer and its protein concentration was deter-
mined. Radioligand binding for [3H]prazosin (PerkinElmer, France)
was performed in a total volume of 100 ll during a 1-h incubation
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at 25°C, using 10 or 100 lg membranes. Experiments were
performed in binding buffer containing 30 mM HEPES, 150 mM
NaCl, 1 mg/ml BSA, pH 7.7 in the presence of 4 nM [3H]prazosin
with or without prazosin or cirazoline. Detection limit is 40–60
receptors/cell. Incubations were terminated by rapid vacuum filtra-
tion over Whatman GF/C filters. Membrane preparations of yeast
expressing the a1-AR (Andre et al, 2006) were used as positive
controls.
Neural lineages differentiation
For oligodendrocytic differentiation, cells were plated onto poly-
ornithine-/laminin-coated plates or slides in expansion medium for
24–48 h. Medium was changed to DMEM/F12 supplemented with
N2, forskolin (10 nM), FGF2 (10 ng/ml), and PDGF (10 ng/ml) for
5 days. From Day 5, medium was switched to DMEM/F12 with N2,
thyroid hormone T3 (30 ng/ml), ascorbic acid (200 lM) all supple-
ments from Stem Cell and PDGF (10 ng/ml) (Miltenyi biotech). On
Day 15, PDGF was withdrawn from culture to allow maturation and
O4 positive could be detected after 5 weeks of differentiation. For
neuronal differentiation, cells were plated on poly-ornithine- and
laminin-coated plates or slides in expansion medium without EGF.
After 10 days, medium was switched to neurobasal, with N2, B27,
and FGF2; 4 days later, FGF2 was withdrawn and 4 days after that,
medium was switched to neurobasal supplemented with B27 + A,
CNTF, and BDNF (Miltenyi biotech). For astrocytic differentiation,
cells were treated with 5% serum. All medium supplements were
from Stem Cell.
Immunocytochemistry
Tumor cell spheres were transferred to polyornithine-coated cover-
slips and allowed to adhere to the coverslips for 20 min at 37°C, 5%
CO2. Cells were fixed with 4% paraformaldehyde for 2 min and
rinsed with phosphate-buffered saline (PBS). Immunocytochemical
staining was performed as previously described (Patru et al, 2010).
Immunofluorescence was observed with a fluorescent microscope
(Eclipse E800, Nikon, USA). Images were acquired with a digital still
camera (DXM 1200, Nikon, http://www.nikoninstruments.com)
using Lucia software (Laboratory Imaging, Ltd, http://www.labora
tory-imaging.com). Images were prepared using Adobe Photoshop
(Adobe Systems).
TUNEL and Ki67 staining
Brains were harvested, fixed in 4% paraformaldehyde at 4C for
24 h, followed by 70% ethanol for 24 h at room temperature, and
embedded in paraffin. For TUNEL staining, brain sections were
stained for cell death using the ApoTag plus Peroxidase In Situ
Apoptosis Detection Kit (Millipore, S7101) as per the manufac-
turer’s instruction. For Ki67 staining, brain sections were treated
with 3% H2O2 for 15 min, followed by Antigen Retrieval for
10 min at 100C in working Tris–EDTA buffer (Abcam ab93684).
Blocking was performed with 10% normal horse serum for 30 min.
Then, sections were exposed to Ki67 antibody for 2 h at room
temperature followed by goat anti-rabbit-biotinylated, 1:500 for
30 min, StreptAvidin–HRP, 1:500 for 30 min, DAB chromogen, and
hematoxylin counterstain. Quantitation was performed using
ImageJ Software on monochrome images by measuring the area of
positive staining.
Immunoblotting
Treated cells were harvested and washed with PBS, and protein
extracts were prepared as previously described (Thirant et al, 2012).
Briefly, cells were lysed in 25 mM PIPES pH 6.8, 1% Triton, 0.5 mM
EDTA, 0.5 mM EGTA, 1 mM sodium orthovanadate, 5 mg/ml
leupeptin, 5 mg/ml pepstatin, 5 mg/ml aprotinin, 1 mM PMSF
(Sigma). Proteins were resolved by 4–12% SDS–PAGE and visual-
ized by immunoblotting with the appropriate antibodies. Signal
detection was performed with the ECL+ chemiluminescence detec-
tion system (PerkinElmer, France). Densitometric analysis was
conducted using ImageJ software.
Luciferase reporter assays
Cell transfection was achieved with the Amaxa Nucleofector Electro-
porator (Amaxa Biosystems, Gaithersburg, MD, USA) according to
the supplier’s instructions, using the Nucleofector program X-005
(70% of transfection efficiency). Cells were suspended in nucleofec-
tion solution (106 cells/100 ll solution, Amaxa Biosystems) and
mixed with 2 lg of the serum response element (SRE)-luciferase
reporter plasmid (Cignal Reporter Assay Kits, SA Bioscence Corpora-
tion, BIOMOL GmbH, Hamburg http://www.sabiosciences.com/
reporter_assay_product/HTML/CCS-010L.html), which allows for
monitoring the activation of the MAPK/ERK signaling pathway.
After 24 h, cells were exposed to the appropriate compounds or
vehicles for 18 h. Quantification of Firefly and Renilla luciferase
activity was performed using the Dual-Luciferase Reporter Assay
System (Promega, France), according to the manufacturer’s instruc-
tions. Renilla luciferase was used for internal normalization of Fire-
fly activity values.
Lentiviral transduction of GICs
The pCDH-CMV-MCS-EF1-puro HIV-based lentiviral vector (Systems
Bioscience, USA) construct contains an ubiquitin promoter driving
the expression of a luciferase-eGFP fusion product (Creusot et al,
2008). The luciferase gene is the Luc2 (pgl4) version (Promega,
USA). The eGFP portion derives from the pIRES2-eGFP plasmid
(Becton Dickinson, USA). Short hairpin RNA for PKCd was from GE
Dharmacon (GIPZ Lentiviral PKCD shRNA: E3-V3LHS_336853 and
F10-V3LHS_637622). Lentiviral production and concentration were
accomplished using standard protocols (Nitta et al, 2015). GICs
were transduced for 12 h at 37°C, 5% CO2, with lentivirus contain-
ing 6 lg/ml polybrene. After 24 h, cells were washed repeatedly to
remove extracellular lentivirus. Cell sorting of eGFP-positive GICs
was performed on a BD FACS ARIA (Becton Dickinson, USA).
Intracranial xenografts
Freshly resected glioblastoma samples were obtained from the
Department of Neurosurgery at Stanford University under approved
institutional review board guidelines (IRB No. 18672) and dissoci-
ated using collagenase IV (1 mg/ml) and DNase I (250 units/ml) in
HEPES-buffered HBSS and treated with ACK/RBC lysis buffer
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(0.15 M NH4Cl, 1.0 mM KHCO3, and 0.1 mM Na2-EDTA). Enrich-
ment in tumor-initiating cells was achieved by sorting EGFR+/
CD133+ cells after immunolabeling of the primary cell suspension
with anti-CD133-APC and anti-EGFR-Alexa 488 using a BD FACS
ARIA (Becton Dickinson, USA). The cells were then plated for
neurosphere formation, as previously described (Emlet et al, 2014).
Passage 1 neurospheres were dissociated and transduced with a
GFP-luciferase-encoding lentivirus, as described above. After
secondary neurosphere formation, eGFP-positive cells were
double-sorted to obtain a pure population of eGFP-positive neuro-
sphere cells and 100,000 cells were injected stereotaxically into the
striatum of anesthetized 6- to 8-week-old NOD scid gamma (NSG)
mice, using the following coordinates: 2 mm posterior to the
bregma, 2 mm lateral to the midline, and 3–4 mm deep with respect
to the surface of the skull. For immunocompetent model, GL261
cells were injected into C57Bl/6 mice. Luminescent imaging was
performed 90 days (for GBM44) and 240 days (for GBM5) after
injection on an IVIS Spectrum (Caliper Life Science) and quantified
using Living Image 4.0 software. D-luciferin (firefly) potassium salt
solution (Biosynth) was prepared (16 mg/ml) and injected intraperi-
toneally (0.139 g luciferin per kg body weight). Total flux (photons
per second) values were obtained by imaging mice until peak radi-
ance was achieved and quantified with Live Image 4.0 software.
Eleven mice were grafted for each group of treatment. Once tumor
masses were detected, mice were randomized in two groups and
prazosin (1.5 mg/kg or 0.15 mg/kg) or DMSO were delivered
intraperitoneally twice a week for 45 days. Bioluminescent imaging
was repeated at the end of the treatment and analyzed in a blind
manner. At least two mice were euthanized at the end of the treat-
ment for further histological examination. The remaining mice were
used to assay survival (at least n = 8 per group of treatment). For
histological analysis, the brains were kept in 4% paraformaldehyde
at 4°C for 24 h, followed by 70% ethanol at room temperature for
24 h. Brains were then embedded in paraffin for 3 h at 67°C.
Coronal sections (5 lm thick) were stained with hematoxylin and
eosin, and images were acquired (Eclipse E800, Nikon, USA).
All animal maintenance, handling, surveillance, and experimenta-
tion were performed in accordance with and approval from the
Stanford University Administrative Panel on Laboratory Animal
Care (Protocol 26548).
Flow cytometry
Mice were euthanized, and brain tumors were dissociated to single
cells and stained with anti-CD133-APC or anti-CD15 or anti-EGFR
(Miltenyi) or Annexin V-PE (BioLegend) and DAPI. Tumor cells
were gated based on GFP expression, and mouse cells were gated
out using a lineage mixture of Pacific blue-conjugated H2kb, H2kd
Ter119, CD31, and CD45 antibodies. Flow cytometric analysis
and cell sorting were performed on a BD FACS ARIA II (Becton
Dickinson).
Statistical analysis
Viability, proliferation, luciferase, and cell death experiments were
performed in biological quadruplicates, in three independent exper-
iments. Western blots, immunofluorescence, and flow cytometry
images are representative from three independent experiments.
Results are presented as mean  SD unless otherwise presented.
Results were analyzed using nonparametric two-tailed Mann–
Whitney test to compare two groups. The level of significance was
set at P < 0.05, as compared with the control group. Kaplan–Meier
survival curves were compared using the log-rank (Mantel–Cox)
test. Statistical analyses were carried out with Prism 6.0 software
(GraphPad).
Expanded View for this article is available online.
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Problem
Glioblastoma is the most common and aggressive form of primary
malignant brain tumor and has a very poor prognosis, mainly due to
the glioblastoma-initiating cells (GICs). Since the current standard of
care for glioblastoma is unable to eliminate the GICs, it is imperative
to identify GIC-targeted therapies, especially those without major
deleterious side effects on normal cells.
Results
Here, we found that prazosin, an a-adrenergic receptor antagonist,
induces selective apoptosis of patient-derived GICs and differentiated
GICs. We show that prazosin treatment inhibits glioblastoma growth
in orthotopic xenograft mouse models and increases mice survival,
with no toxicity. We provide evidence that the prazosin-induced GIC
apoptosis occurs through PKCd-dependent inhibition of AKT pathway,
independent from adrenergic receptors.
Impact
Our findings identify prazosin as a potent inhibitor of glioblastoma
growth. Prazosin is an FDA-approved drug with a record of over
40 years of safe and effective clinical use. Prazosin-induced GIC apop-
tosis associated with the well-established and documented use of this
drug in clinical settings opens a promising possibility for its use in
glioblastoma treatment.
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